American College of Clinical Pharmacy
      Search      Cart
         

ACCP News Archives

To read previous news articles, click on any of the article titles below.

2017

ACCP Testifies Before House Committee on Appropriations
Free, NIH-Funded Clinical Research Resources for Critical Care
ACCP Releases Clinical Pharmacist Competencies and New Template for Clinical Pharmacist Evaluation
Highlights from the CMM Effectiveness and Implementation Grant: A Report from the Study Team
Letters of Intent for Investigator Training Programs
Call for Nominations
2017 ACCP Clinical Research Challenge Under Way
Washington Report: ACCP Board of Regents Approves Position Statement: “Optimizing Specialty Drug Use”
Guidelines for Pharmacotherapy Authorship
FDA Approves BAVENCIO (avelumab)
FDA Approves ZEJULA (niraparib)
FDA Approves ALUNBRIG™ (Brigatinib)
From the Desk of the ACCP President
FDA Approves OCREVUS (Ocrelizumab)
Board of Pharmacy Specialties® Issues call for Petition in Solid Organ Transplantation
FDA Approves IMFINZI™ (Durvalumab)
Board of Pharmacy Specialties® Issues call for Petition in Solid Organ Transplantation
FDA Approves RYDAPT® (Midostaurin)
FDA Webinar on Presenting Clinical Pharmacology Information in Prescription Drug Labeling
Call for Emergency Medicine Subject Matter Experts
Pharmacotherapy Impact Factor Increases to 2.932
FDA Approves Gleolan [aminolevulinic acid hydrochloride (ALA HCl)] as an Optical Imaging Agent Indicated in Patients with Gliomas (suspected World Health Organization Grades III or IV on preoperative imaging) as an Adjunct for the Visualization of Malignant Tissue During Surgery
Report of the Nominations Committee
The WEBBlog: A Series of Occasional Commentaries on Policy, Politics, and Practice in the World of Clinical Pharmacy
As “DRGs” (sort of) Find Their Way into Clinical Pharmacist Practice Outside the Hospital … What to Do?
ACCP Member Publication in Pharmacotherapy Contributes to FDA Safety Warning
ACCP to Launch New Journal
NEW ACCP Updates in Therapeutics® 2018
FDA Announces Two New Draft DDI Guidances
FDA Approves CALQUENCE (Acalabrutinib)
The WEBBlog: A Series of Occasional Commentaries on Policy, Politics, and Practice in the World of Clinical Pharmacy
Why a Pharmacy Team is Essential to Achieving Optimal Medication Use for Patients and Their Health Care Team
FDA Announces Availability Of The Draft Guidance, “Developing Targeted Therapies In Low-Frequency Molecular Subsets Of A Disease”